Helper-dependent adenoviral vector has demonstrated a high therapeutic potential; however, the poor efficiency of the actual production process hampers further large-scale clinical evaluation. In this work, we evaluated the adenofection protocol, an efficient polyethylenimine transfection strategy, for HDV production. Optimized conditions of PEI-adenofection were used to generate HDV at 3-L bioreactor scale. This process strategy realized in suspension reduced process duration and therefore ensured production of high-quality vector stock.
Cells and Culture: Proceedings of the 20th ESACT Meeting, Dresden, Germany, June 17-20, 2007: 441–445.